pebble 2

In 2023, we set up a new investment company alongside Tiger Jade Capital and Tigermed (HKEX: 3347) to continue our investment strategy, but with the support and backing of Tigermed - China's largest clinical CRO. We also expanded our scope of work to include consulting and financial advisory projects, given a notable market demand for our team's services and the strength of our network.

​

The Pentepebble Portfolio is now a closed portfolio but remains under active management. Our work is continued at the Tiger Jade Pebble Accelerator.